CRIS Current Research Information System

MARZOCCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.549
NA - Nord America 3.366
EU - Europa 2.226
AF - Africa 208
SA - Sud America 156
Continente sconosciuto - Info sul continente non disponibili 132
OC - Oceania 7
Totale 9.644
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.298
VN - Vietnam 1.384
CN - Cina 799
SG - Singapore 756
IT - Italia 481
GB - Regno Unito 458
SE - Svezia 307
DE - Germania 261
HK - Hong Kong 186
FR - Francia 142
IN - India 131
NL - Olanda 122
BR - Brasile 111
RU - Federazione Russa 103
KR - Corea 78
IE - Irlanda 71
UA - Ucraina 63
CI - Costa d'Avorio 56
FI - Finlandia 50
ZA - Sudafrica 47
SC - Seychelles 39
JP - Giappone 38
TG - Togo 37
BD - Bangladesh 35
CA - Canada 35
EE - Estonia 33
BG - Bulgaria 30
CH - Svizzera 29
JO - Giordania 27
AR - Argentina 22
PH - Filippine 22
TH - Thailandia 21
BE - Belgio 18
MX - Messico 17
NG - Nigeria 12
AT - Austria 11
CL - Cile 11
TW - Taiwan 11
IR - Iran 10
TR - Turchia 10
ES - Italia 9
PL - Polonia 9
SA - Arabia Saudita 8
GR - Grecia 7
ID - Indonesia 7
CZ - Repubblica Ceca 6
AU - Australia 5
IQ - Iraq 5
CR - Costa Rica 4
IL - Israele 4
KE - Kenya 4
MY - Malesia 4
DZ - Algeria 3
EC - Ecuador 3
GT - Guatemala 3
MA - Marocco 3
PK - Pakistan 3
PY - Paraguay 3
CO - Colombia 2
HN - Honduras 2
JM - Giamaica 2
LT - Lituania 2
NI - Nicaragua 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GM - Gambi 1
GP - Guadalupe 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
NC - Nuova Caledonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
UY - Uruguay 1
UZ - Uzbekistan 1
YT - Mayotte 1
Totale 9.512
Salva come PNG Salva come JPEG
Città #
Singapore 541
Southend 392
Ashburn 380
Ho Chi Minh City 307
Chandler 297
Fairfield 274
Hanoi 237
Dong Ket 207
Hong Kong 180
San Jose 175
Hefei 167
Woodbridge 152
Seattle 137
Wilmington 127
Houston 123
Cambridge 115
Ann Arbor 114
Bologna 111
Beijing 109
Princeton 85
Dallas 84
Seoul 74
Santa Clara 73
Dublin 71
New York 69
Boardman 68
Abidjan 56
Council Bluffs 50
Lauterbourg 49
Helsinki 44
Turin 40
Lomé 37
Los Angeles 37
Nanjing 37
Westminster 36
Padova 34
Haiphong 33
Milan 33
Bremen 32
Jacksonville 30
Sofia 30
Tokyo 29
Berlin 27
Amman 26
Florence 26
Jinan 26
Da Nang 24
Frankfurt am Main 24
Munich 24
Hyderabad 22
Bern 20
São Paulo 20
Buffalo 19
Redondo Beach 19
Saint Petersburg 19
Shenyang 19
Biên Hòa 18
Brussels 18
San Diego 18
Guangzhou 17
Bengaluru 16
Nanchang 15
Can Tho 14
Ha Long 14
Tianjin 14
Thái Nguyên 13
Atlanta 12
Hebei 12
Orem 12
Quận Bình Thạnh 12
Redmond 12
Redwood City 12
Zhengzhou 12
Abeokuta 11
Brooklyn 11
Nuremberg 11
Phoenix 11
Toronto 11
Castelfranco Emilia 10
Falkenstein 10
Hangzhou 10
Paris 10
San Francisco 10
Shanghai 10
Amsterdam 9
Falls Church 9
London 9
Quận Một 9
Casalecchio di Reno 8
Chengdu 8
Düsseldorf 8
Johannesburg 8
Taizhou 8
Bắc Ninh 7
Changsha 7
Chicago 7
Des Moines 7
Hải Dương 7
Ninh Bình 7
Santiago 7
Totale 6.072
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 361
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 347
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 257
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 253
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 231
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 226
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 217
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 214
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 214
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 214
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 210
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 209
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 206
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 204
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 197
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 189
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 185
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 184
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 183
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 181
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 179
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 178
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 171
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 167
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 165
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 162
Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. 160
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 160
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 159
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 157
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 156
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 156
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 156
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 148
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 142
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 134
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 125
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 113
null 104
null 102
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 100
Proteasome inhibitors: Bortezomib in multiple myeloma 94
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 65
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 49
Totale 9.644
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.138
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.138
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022825 0 0 54 98 78 41 21 58 41 113 162 159
2022/20231.167 115 188 59 164 65 92 38 68 189 36 112 41
2023/2024381 23 42 22 39 38 103 14 31 6 18 28 17
2024/20251.197 65 108 91 101 150 54 106 43 16 176 76 211
2025/20263.398 325 755 281 223 310 148 260 92 578 228 96 102
2026/2027175 54 117 4 0 0 0 0 0 0 0 0 0
Totale 9.644